BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, November 19, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector
  • Gears traveling between drug capsule and head

    SfN 2025: How ‘latent’ sex differences can trip up drug discovery

    At the 2025 annual meeting of the Society for Neuroscience in San Diego this week, Catherine Woolley’s plenary lecture was an unusual combination of debunking and affirming the importance of sex differences in the brain.
  • Harbour Biomed launches AI-based antibody development platform

  • Radiopharm’s RAD-402 gains HREC approval in Australia for phase I

  • IO-112 is novel cancer vaccine harnessing Arg1-specific immunity

  • SfN 2025: How ‘latent’ sex differences can trip up drug discovery

    At the 2025 annual meeting of the Society for Neuroscience in San Diego this week, Catherine Woolley’s plenary lecture was an unusual combination of debunking and affirming the importance of sex differences in the brain.
  • Harbour Biomed launches AI-based antibody development platform

    Harbour Biomed is stepping up its antibody discovery process by using AI to develop innovative therapeutics. “We have done great through the traditional way of generating leads and designing molecules, but there’s a major gap as some therapeutics cannot reach the desired location or common targets,” Harbour Biomed founder, chairman and CEO Jingsong Wang told BioWorld.
  • Radiopharm’s RAD-402 gains HREC approval in Australia for phase I

    Radiopharm Theranostics Ltd. has been granted Bellberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I trial of its KLK3-targeting radiotherapeutic, RAD-402, for the treatment of metastatic or locally advanced prostate cancer.
  • IO-112 is novel cancer vaccine harnessing Arg1-specific immunity

    Arginase 1 (Arg1) is a key mediator of immune suppression, and its overexpression has been reported in multiple cancers, including renal cell carcinoma, pancreatic cancer, and head and neck cancer. However, clinical strategies aimed at inhibiting Arg1 function have achieved only limited success.
  • Triple whammy: Ternary hybrid molecules to stop breast cancer

    Anticancer drugs that work simultaneously through multiple mechanisms are sought after because of their potential for greater efficacy and robustness to resistance. Researchers at Capital Medical University and Chinese Institutes for Medical Research generated 21 ternary hybrids containing phenylsulfonylfuroxan, b-carboline und hydroxamic acid moieties.
  • Mabloc and Instituto Butantan partner on MBL-YFV-01

    Mabloc LLC has established a strategic partnership with Instituto Butantan to co-develop and manufacture MBL-YFV-01, a monoclonal antibody therapy for yellow fever virus (YFV) infection, including emergency post-exposure use.
  • Yichang Humanwell Pharmaceutical patents new κ-opioid receptor agonists

    Yichang Humanwell Pharmaceutical Co. Ltd. has disclosed morphinan derivatives acting as κ-opioid receptor agonists reported to be useful for the treatment of pain and pruritus.
  • CT-111 trispecific antibody promotes cooperative antitumor effects

    Researchers from Chantibody Therapeutics Inc. presented the preclinical characterization of CT-111, a trispecific antibody engineered to simultaneously target PD-1, CTLA-4, and VEGF.
  • Oral cyclin D1-selective inhibitors with antitumor activity, improved safety profile

    Microscope with laptop displaying histology image.
  • Hangzhou Zhongmei Huadong Pharmaceutical divulges new GTPase KRAS inhibitors

  • Hutchmed describes new antibody-drug conjugates

  • Modex’s MDX-2004 enhances antitumor immunity, study shows

    Illustration of cancer cell in crosshairs being destroyed
  • New GSPT1/CSNK1A1 degradation inducers disclosed in Mindrank patent

  • Zhuhai United Laboratories discovers new β-lactamase inhibitors

  • NTS-231 is molecular glue for inhibiting aberrant NRF2 activation

    Pill over molecule structures
  • NME Digest Series

Sponsored content

Conferences

  • Floating antibody drug conjugates

    CEACAM5-targeting ADC with a highly potent pan-RAS(ON) inhibitor payload

    New compound
    Although tricomplex pan-RAS (ON) inhibitors, such as RMC-6236, constitute a promising class of therapeutics against RAS-driven cancers, their on-target, off-tumor toxicities challenge the dosing strategy and the safety of drug combinations.
  • Small-molecule p53 Y220C reactivators with enhanced potency presented

    New compound
    Inactivation of the tumor suppressor p53 occurs in approximately half of human cancer cases. In particular, the Y220C point mutation, which induces p53 misfolding and inactivation, is found in about 1% of solid tumors. Previous research identified a unique, druggable pocket on the p53 surface...
  • RVU-305 shows potential against GBM in preclinical studies

    AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
    In glioblastoma multiforme, MTAP loss leads to MTA accumulation, which partially inhibits PRMT5, making the cells reliant on residual PRMT5 activity for survival. Targeting this remaining PRMT5 with MTA-cooperative inhibitors induces synthetic lethality, representing a promising targeted approach...
  • Synergistic antiviral efficacy of HEC-191834 with siRNA in HBV models

    American Association for the Study of Liver Diseases
    In preclinical studies at Sunshine Lake Pharma Co. Ltd., researchers investigated the antiviral and immune-modulatory potential of HEC-191834, a novel and highly selective human Toll-like receptor 8 (TLR8) agonist, in chronic hepatitis B virus (HBV) models, as well as its activity when combined...
More in Conferences

Today's news in brief

  • Respiratory

  • Dermatologic

  • Cardiovascular

  • Hematologic

  • Nephrology

Patents

  • Shanghai Phrontline Biopharma discovers new antibody-drug conjugates

  • New GTPase KRAS mutant inhibitors disclosed in Adlai Nortye patent

  • Idorsia Pharmaceuticals describes new OX2 receptor agonists

  • Inventisbio divulges new WRN inhibitors

  • Samjin Pharmaceutical patents new compounds for MASH

  • Pretzel Therapeutics discovers new POLG modulators

  • New PTPN2/PTP1B degraders disclosed in Northridge Health patent

  • Circle Pharma describes new CDK inhibitors

  • Assembly Biosciences divulges new viral replication inhibitors

  • Imhotex patents new NOD2 activators for Crohn’s disease

Cancer

  • Haisheng Zhang, CEO, Signet

    Signet builds new model for gastric cancer drug discovery

    Newco news
    Signet Therapeutics founder Haisheng Zhang is betting on organoids and AI to outsmart diffuse gastric cancer and the limits of traditional “clean” drug design.
  • ‘Most complete’ map of oral microbiome enables links to systemic disease

    Artificial intelligence
  • Targeting P-gp to inhibit drug efflux, autophagic flux in breast cancer

  • T-knife files CTA for TCR T-cell therapy for solid tumors

    Regulatory
  • Captain T Cell raises funds to advance TCR-T pipeline

    Financings
More in Cancer

Infection

  • Test tubes, dropper and capsules

    Scynexis fungerps among funding recipients

    Scynexis Inc. has announced that a novel series of antifungal compounds utilizing its proprietary triterpenoid antifungal platform are among five projects funded by a federal grant awarded to the new accelerator consortium led by researchers from Hackensack Meridian Center for Discovery and...
  • GSK and Fleming Initiative announce AMR research programs

    Artificial intelligence
    GSK plc and the Fleming Initiative have announced six major new research programs to find new ways to slow the progress of antimicrobial resistance (AMR). The Fleming Initiative is a collaboration established by Imperial College London and Imperial College Healthcare NHS Trust to help tackle AMR....
  • Anti-malarial targets P. falciparum phosphatidylinositol 4-kinase with reduced toxicity

    In an effort to generate an effective and safer inhibitor, researchers at the University of Cape Town, University of Dundee and Massachusetts Institute of Technology used structure-guided rational design to improve on their previously reported 2,8-diaryl-1,5-naphthyridine inhibitor.
  • Dual-antigen mRNA vaccine protects against lethal DBV challenge

    Immune
  • ‘Most complete’ map of oral microbiome enables links to systemic disease

    Science
  • Aligos and KU Leuven divulge new antivirals

    Coronavirus
  • Agents for Acinetobacter infections named in Chinese Academy of Medical Sciences patent

    Patents
More in Infection

Neurology/psychiatric

  • Amyloid plaques on nerve cell

    Akeso’s AK-152 gains IND clearance in China for Alzheimer’s

    Regulatory
    Akeso Inc. has received clearance from China’s National Medical Products Administration (NMPA) to initiate clinical trials with AK-152 for Alzheimer’s disease.
  • Man pulling back clouds for sunshine

    Adenosine surge is common thread in ketamine and ECT response

    Science
    Researchers from the Chinese Institute for Brain Research, the Chinese Academy of Medical Sciences, and their collaborators have identified adenosine as the driving force behind the rapid, fast-acting antidepressant effects of ketamine and electroconvulsive therapy (ECT). “Our journey into this...
  • Shanghai Innoxtal Therapeutics patents new Nav1.8 blockers

    Patents
    Shanghai Innoxtal Therapeutics Co. Ltd. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia and urinary incontinence.
  • Drosophila melanogaster (fruit fly) on a blade of grass

    Drosophila genetic screening reveals mechanisms behind AD pathology

    Researchers from the Baylor College of Medicine have characterized 100 conserved Alzheimer’s disease (AD) risk orthologue genes in Drosophila and found several with unknown roles in brain structure, function and stress resilience. The implication of this finding is that new pathways of...
  • Brain with handshake and cityscape

    Transition Bio and Voyager Therapeutics partner in ALS and FTD

    Collaboration
    Transition Bio Inc. and Voyager Therapeutics Inc. have entered into a drug discovery collaboration and license option agreement for novel, selective small molecules for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) with TDP-43 pathology.
More in Neurology/psychiatric

Immune

  • ‘Encyclopedia’ of xenotransplantation reveals drivers of immune rejection

  • QEL-005 restores homeostasis in inflammatory disorders

  • NKX-019 induces CD19 depletion in autoimmune disease

  • Commit Biologics’ complement engager platform studied in NHPs

  • Inje University discovers new PDPK1 inhibitors

  • Azalea exits stealth to develop its in vivo gene engineering technology

  • CDR-Life’s new dual-targeting T-cell engager

  • Microglia acting like T cells mitigate Alzheimer’s progression

  • Pentacyclic derivatives for autoimmune diseases disclosed in Hansoh patent

  • Boehringer Ingelheim licenses CDR-Life’s CDR-111

Endocrine/metabolic

  • Illustration of adipose tissue under the skin

    Mitorx Therapeutics raises funds to advance Myo-004 for obesity

    Financings
    Mitorx Therapeutics Ltd. has raised £5.5 million (US$7.2 million) in a pre-series A round to advance its lead mitochondrial-targeted program, Myo-004, through clinical candidate selection.
  • New GIPR antagonists disclosed in Pfizer patent

    Patents
  • Century Therapeutics unveils β islet program for type 1 diabetes

  • CGX-926 corrects MC4R deficiency-driven obesity

    Conferences
  • 35pharma’s HS-235 as new approach for obesity treatment

    Conferences
More in Endocrine/metabolic

Biomarkers

  • Art concept for medical research

    With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

    Neurology/psychiatric
    Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical settings. Many individual studies as well as large projects like the Psychiatric Ratings using Intermediate Markers (PRISM) studies and the...
  • Anchoring, and bootstrapping, psychiatry into the precision medicine era

    Neurology/psychiatric
    Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are working on improving diagnoses by investigating potential biomarkers and collection methods.
  • Biomarker panel of three serum microRNAs predicts cervical cancer prognosis

    Cancer
    MicroRNAs (miRNAs) play key roles in cancer development by regulating genes involved in cell growth, differentiation, invasion, metastasis and angiogenesis. Because their expression patterns differ across tumor types and stages, miRNA profiles hold strong potential as noninvasive diagnostic and...
  • LINC01354 is a prognostic marker in esophageal cancer

    Cancer
  • FGF5 gene involved in excessive hair growth

    Conferences
  • Study identifies REST as biomarker and siRNA target in ALS

    Neurology/psychiatric
  • New link between PRRX1 gene and open-angle glaucoma

    Conferences
More in Biomarkers

Gastrointestinal

  • Numab and Kaken sign agreement for NM-81 for IBD

    Collaboration
    Numab Therapeutics AG and Kaken Pharmaceutical Co. Ltd. have entered into a strategic licensing and co-development agreement for NM-81, a multi-specific antibody for the treatment of inflammatory bowel disease (IBD).
  • Korro Bio nominates KRRO-121 as development candidate

    Endocrine/metabolic
    Korro Bio Inc. has nominated KRRO-121 as its next development candidate, for the treatment of patients with hyperammonemia, including patients with urea cycle disorders and hepatic encephalopathy.
  • Genfit and Everzom form research collaboration in liver failure

    Collaboration
    Genfit SA has established a research collaboration with Everzom SAS to expand its acute-on-chronic liver failure (ACLF) research via exosome-based regenerative technology. The partners plan to conduct exploratory studies to assess efficacy of...
  • Eilean presents in vivo data on MALT1 degrader TE-205

    Degradation inducer
    Eilean Therapeutics LLC has presented in vivo data for its first-in-class MALT1 degrader, TE-205, as a disease-modifying therapy for ulcerative colitis.
  • Interline Therapeutics patent reports RIPK2 inhibitors for IBD

    Patents
    Interline Therapeutics Inc. has identified new compounds receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD).
  • Daewon Pharm patent reveals new H+/K+-ATPase inhibitors

    Patents
    Daewon Pharmaceutical Co. Ltd. has reported new compounds acting as H+/K+-ATPase inhibitors useful for the treatment of reflux esophagitis.
More in Gastrointestinal

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple backgroundBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.


Recent episodes:

  • Esperion Therapeutics CEO Sheldon Koenig
  • Trying this at home: Bioxcel steps closer to an sNDA for Igalmi
  • The importance of balancing AI and people in drug development
  • Two CEOs discuss bracing for tariffs, NIH grant cuts and
    gifting China biopharma leadership position
  • As biopharma investments stumble, med tech surges
  • Mega money well spent? Mammoth mergers fall short of the dream
  • Healing the health divide for women
  • Modifi gets creative on the rocky road to a multibillion-dollar buyout
  • A quantum leap into the future of drug development
  • Gene and cell therapies will propel innovation, says Astellas CCO

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, BioWorld Science and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing